Cytokinetics Poised to Begin Phase 3 after its HCM Drug Registers Encouraging Data
South Francisco, California-based Cytokinetics, Inc. has created an uproar again by announcing positive study findings for an investigational heart drug, CK-274, for treating a chronic cardiovascular disease, Hypertrophic Cardiomyopathy (HCM). …
Read More